Management of Metastatic Colorectal Cancer : A Case Series of 20 Patients
Elwassi Anas
Department of General Surgery, IBN ROCHD University Hospital of Casablanca, Casablanca, Morocco.
Belbsir Mohamed *
Department of General Surgery, IBN ROCHD University Hospital of Casablanca, Casablanca, Morocco.
Kenza Benjelloun Touimi
Department of General Surgery, IBN ROCHD University Hospital of Casablanca, Casablanca, Morocco.
Hajri Amal
Department of General Surgery, IBN ROCHD University Hospital of Casablanca, Casablanca, Morocco.
Erguibi Driss
Department of General Surgery, IBN ROCHD University Hospital of Casablanca, Casablanca, Morocco.
Boufettal Rachid
Department of General Surgery, IBN ROCHD University Hospital of Casablanca, Casablanca, Morocco.
Rifki Jai Saad
Department of General Surgery, IBN ROCHD University Hospital of Casablanca, Casablanca, Morocco.
Chehab Farid
Department of General Surgery, IBN ROCHD University Hospital of Casablanca, Casablanca, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Metastatic colorectal cancer (mCRC) represents a major public health challenge, characterized by high morbidity and mortality. This retrospective study, conducted at Ibn Rochd University Hospital in Casablanca from 2019 to 2023, analyzes the epidemiological, clinical, and therapeutic characteristics of 20 patients diagnosed with mCRC. The mean age was 56 years, with a male predominance. The liver was the most common metastatic site. Management relied on a multidisciplinary approach combining surgery, chemotherapy, and, in selected cases, radiotherapy. The FOLFOX regimen was the most frequently administered. The resectability rate of liver metastases was 40%. Median overall survival was 12.6 months. Recent advances, such as personalized medicine and liver transplantation, offer new opportunities for improving survival and quality of life in these patients.
Keywords: Metastatic colorectal cancer, therapeutic advancements, Colorectal Cancer, metastases